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Average and individual sets of plasma concentration-time data for acetaminophen following two 
oral treatments were simuItaneously fitted to the integrated equation describing the two-compartment 
open model with first-order absorption and lag time. The nonlinear least-squares program NON LIN 
and an IBM 360/67 digital computer were employed to estimate nine parameters (k A, kB, C ~ C ~ 
k12 , k21, kel , toA and to8 ). When the mean plasma concentrations were weighted according to the 
inverse of their variances, the parameter estimates more accurately reflected those for individual 
subjects in the disposition portion of the model. Depending on the relative magnitudes of the 
disposition rate constants (k 12, k2 t, and k~0, the one-compartment open model can be used to predict 
equilibrium-state plasma levels even though the drug is really "two compartment." Equations are 
presented which show when the one-compartment approximation is justified. Equations are also 
presented for calculation of loading doses for multiple dose regimens of any drug obeying the two- 
compartment open model and the equations are applied to acetaminophen. 
K E Y  W O R D S :  acetaminophen; oral administration; plasma levels; simultaneous fitting; 
weighting factor; central compartment correction factor. 
I N T R O D U C T I O N  
The utility of pharmacokinetics for quantification of drug absorption 
and disposition is well documented (1). The approach permits predictions 
regarding drug dosage adjustment and, in addition, allows for comparison 
of the effects of dosage form variables on therapeutic efficacy and/or bio- 
availability. In a recent study, Albert et al. (2) noted differences in rates of 
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absorption of acetaminophen when the drug was administered separately 
to ten healthy volunteers both as a commercial tablet and as a specially 
formulated soft gelatin capsule. In this report, the pharmacokinetic model 
which was elaborated from the plasma concentration-time data will be 
discussed. 
EXPERIMENTAL 
Treatment of Data 
The study conditions were described in a previous report (2). Average 
and individual sets of plasma concentration-time data obtained following 
two oral treatments of acetaminophen were simultaneously fitted to the 
integrated equation describing the two-compartment open model with 
first-order absorption and lag time to (Model I and equations A1 and A2 of 
the Appendix). The nonlinear least-squares program NONLIN and an 
IBM 360/67 digital computer were employed. The nine parameters esti- 
mated, corresponding to Model I, were ka, kn, k12, k21, kel, C ~ (FaD/VO, 
C ~ (FBD/VO, toA, and to~ where the subscripts A and B refer to treatments 
A (soft gelatin capsule) and B (commercially available tablet). 
k. f. , I k0~ F D a t t = t ~  o~--~, A '  
Model I 
Estimates of the parameters were obtained by minimizing the sums of the 
weighted deviations, i.e., E~'= 1 wi(t2~ - C;) 2, where wi is the weighting factor, 
Ci is the estimated concentration, and C~ is the observed concentration at 
time ti. The mean plasma concentrations in separate trials were weighted 
(a) equally ; (b) according to the inverse of their concentrations, 1/Ci; (c) ac- 
cording to the inverse of the square of their concentrations, 1/(Ci)2;  and 
(d) according to the inverse of their individual variances, 1/azi. Individual 
subject concentrations were weighted according to i/Ci and 1/C~. 
Criteria used to assess adequate fit of the data to the model were (a) r z, 
the coefficient of determination, equivalent to (Z Obs 2 - E DevZ)/Y~ Obs 2 ; 
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(b) Corr, the correlation coefficient for the linear regression of the model- 
predicted plasma concentration vs. observed plasma concentration ; (c) lack 
of trends or regions of poor  fit as delineated by a plot of the weighted residual 
(weight x % deviation) vs. observed plasma concentration; and (d) the 
magnitudes of the coefficients of variation of the estimated parameters 
(standard deviation of the estimate/estimated parameter). 
Weighting Considerations 
Equation 1, which describes a relationship between variance and con- 
centration, may be used to test a feasible weighting factor (wi) for fitting 
individual subject plasma concentrations to a model based on the mean 
plasma levels of the panel of subjects to which the individuals belong: 
~2 = a .  (C)" (1) 
where a 2 is the variance corresponding to mean concentration C and a and 
n are constants. Taking logarithms of both sides of equation 1 gives equation 2: 
In a 2 = lna  + nln C (2) 
Plotting In a 2 vs. In C generates a straight line with intercept In a (corre- 
sponding to C = 1) and slope n. If n = 1, w~ = 1/Ci; if n = 2, wi = 1/C~. 
This is a reasonable method for estimating the appropriate weights for an 
individual subject set of plasma level data since there is only one observation 
at each time. Adherence to equation 2 indicates that the trends in variance 
across a concentration-time curve are due only to the magnitude of the 
plasma concentrations and are independent of time or other effects. If the 
correlation coefficient is very high for the averages (i.e., for the mean plasma 
levels) when equation 2 is applied, then one could use w i = 1/a(C)" to fit 
average plasma concentrations, or one could still use the weighting factor 
1/a~ (as we chose to do) where a~ is calculated from the panel's concentrations 
at each time t~. In using the variance of mean plasma concentrations, the 
sampling times have to be the same for each subject, as they were in our 
study. 
Theoretical Treatment of Disposition Rate Parameters 
The microscopic rate constants k12 , k21 , and kel which describe the 
disposition portion of Model I can be used to estimate how well C,t data 
can be approximated by the one-compartment open model. Equation 3, 
applicable to the two-compartment open model with rapid intravenous 
injection 3 (see Appendix), shows that as B/(A + B) ~ 1, the model reduces 
3The same conclusions would apply for first-order absorption. 
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to the one-compartment open model, because the first term on the right-hand 
side vanishes since A ~ O. 
C , / C  ~ = [A/(A + B)] e-~'t + [B/(A + B)] e -~' (3) 
In equation 3, B / ( A + B ) = ( k 2 1 - f l ) / ( ~ - f l )  and C o = A + B .  The 
"collapsing," if it occurs, depends on the relative magnitudes of k21, ~t, and 
ft. However, specifically, as k21 ~ ~, "collapsing" occurs. Equation 3 also 
indicates that if k 2~ >> fl and ~ >> fl, then the ratio B/(A + B) ~- fl/k~l = 
k21/~. 
Sometimes, for drugs which actually obey the two-compartment open 
model, the one-compartment open model can be used to predict average 
steady-state amounts of drug in the body during multiple dosing. For the 
one-compartment model, 
71~ = FD/fl~ (4) 
where A~ represents the average amount of drug in the body at the equili- 
brium state and z represents the dosage interval. An analogous expression, 
derived in the Appendix, can be written for the two-compartment open 
model: 
Aoo = [fl/ke,(1 + k12/k21)Fn]/fl z (5) 
It is apparent that when the factor fl/kr + k12 /k21 )~  1, equation 5 
reduces to equation 4 and the one-compartment open model would accurately 
predict Ao0. This factor may be viewed as a central compartment correction 
factor (CCCF) for the two-compartment open model compared with the 
one-compartment open model. 
Equation 5 can be rearranged to equation 6 to provide the "accumula- 
tion ratio" (RA) for the two-compartment open model as described by 
Wagner (3): 
RA = Aoo/FD = (1 + k12/k21)/kel'C (6) 
RA is equal to the average amount of drug in the body during a dosage 
interval at the equilibrium state divided by the amount of drug absorbed 
following a single maintenance dose. Since RA can be estimated from the 
parameters of the two-compartment model, the loading dose for a multiple 
dosing regimen can be calculated using equation 7: 
Loading dose = RA" maintenance dose (7) 
The central compartment correction factor is of particular importance 
in estimating loading doses since the loading dose using the two-compart- 
ment equation (equation 6) will always be less than the loading dose esti- 
mated using the one-compartment equation (equation 4) for equal main- 
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tenance doses. It is possible that with some drugs toxicity problems are 
caused by use of  the inappropr ia te  model  to estimate the loading dose. 
R E S U L T S  
Table  I lists the pharmacokine t ic  parameters  obta ined by s imultaneously 
fitting mean  plasma concentra t ions  of  ace taminophen  to Model  I and  equa- 
t ions A1 and  A2 of  the Appendix.  In  such s imultaneous fitting, the weighted 
sum of squared deviations of  bo th  sets of  data  is minimized. With the excep- 
tion of  wi = 1/a~, the weighting factors had little influence on the parameter  
estimates and their cor responding  coefficients of  variation. Use  of  w i = 1/a~ 
gave different values for the parameters  and higher coefficients of  variat ion 
of  the estimates. 
Table I I  gives the parameter  estimates f rom simultaneous fitting of  the 
two sets of  C , t  data  for each subject to Model  I employing the weighting 
factors 1/Ci  and 1 /C  2. Equal  weighting was not  used since the error  in the 
Table L Parameter Estimates and Coefficients of Variation for Mean Plasma Concentrations of 
Acetaminophen 
Estimated parameters and coefficients of variation" 
Equal 1/C i 1/(Ci) 2 1/a 2 
Parameter weighting w e i g h t i n g  w e i g h t i n g  weighting 
kA(h r- 1) 0.991 1.04 1.07 0.764 
(0.157) (0.138) (0.138) (0.268) 
kB(h r - l) 2.03 2.22 2.45 1.27 
(0.211) (0.215) (0.268) (0.372) 
k 12( hr- 1) 0.106 0.0827 0.0707 0.319 
(0.570) (0.494) (0.406) (0.696) 
k2 l(hr- 1) 0.203 0.262 0.246 0.499 
(0.586) (0.382) (0.365) (0.206) 
k~l(hr- 1) 0.324 0.321 0.310 0.472 
(0.146) (0.103) (0.097) (0.339) 
C~ 9.98 9.51 9.18 13.7 
(0.124) (0.107) (0.109) (0.337) 
C~ 9.38 8.96 8.56 12.9 
(0.112) (0.110) (0.110) (0.336) 
toA(hr ) 0.164 0.165 0.165 0.165 
(0.108) (0.011) (0.017) (0.008) 
t0.(hr ) 0.0342 0.0425 0.0498 0.00252 
(0.705) (0.522) (0.524) (1.18) 
r 2 0.998 0.998 0.998 0.997 
Corr 0.997 0.997 0.996 0.996 
0.502 0.496 0.461 1.07 
fl 0.132 0.169 0.165 0.220 
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Fig. 1. Weighted residual plot for subject 9. O,  Treatment A; ~,, treatment B. 
GLC assay was concentration dependent and this error is a part of the 
total error. 
A paired t-test indicated in each case that the means of the estimates 
obtained using the different weighting schemes did not differ significantly. 
The reasonably high r 2 and Corr values indicated the applicability to the 
data of the two-compartment open model with first-order absorption and 
lag time. In addition, weighted residual plots, a typical example of which is 
shown in Fig. 1, gave no evidence of trends or regions of poor fit. Figures 2 
and 3 graphically compare the observed and model-predicted concentrations 
for subjects 4 and 9. These data represent the worst and best fits, respectively. 
(Although Table II shows that subject 7 gave the worst fit, the observed 
plasma levels indicated that it was impossible to fit these data to any linear 
model. Hence this subject's parameters were not included in any averages.) 
A comparison of the disposition rate parameters in Tables I and II 
reveals that use of w i = 1/o-~ for the mean plasma data more accurately 
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Table IIl. Comparison of Disposition Rate Parameters, Estimated from Mean Plasma 
Concentrat ion Data, with Averages of Individual Subject Parameter  Estimates 
Parameter  estimates 
From mean plasma level curve 
Average of l/C" i 
Parameter  and 1/(C'i) 2 data" 1/cr~ 
Average of parameter from 
individual subject fittings b 
k12 (hr-  1) 0.0767 0.319 0.273 
kz x (hr-  l) 0.254 0.499 0.496 
kei (hr-  1) 0.316 0.472 0.363 
ct (hr-  1) 0.479 1.07 0.940 
fl (hr-  1) 0.167 0.220 0.194 
aObtained by averaging columns headed "I/C~ weighting" and "l/(Ci) 2 weighting" in 
Table I. 
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Fig. 2. Observed vs. model-predicted plasma concentrations of acetaminophen 
for subject 4, representing the worst fit of all subjects; wl = UC~. 0 - -  0, 
Treatment A; ~ ~ ,  treatment B. 
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Fig. 3. Observed vs. model-predicted plasma concentrations of acetaminophen 
for subject 9, representing the best fit of all subjects; w~ = 1/C{. 9 - 0 ,  
Treatment A ; 0 ~), treatment B. 
reflects those derived from individual subject data. This is clearly shown in 
Table III. The observation is not surprising since the pattern of variances 
that occurs across an average blood level curve would be the same pattern 
expected if the same subject were administered the same treatment a large 
number of times. This suggests that equation 2 can be used to estimate the 
appropriate weight for individual subject sets of acetaminophen data using 
the mean plasma levels of the panel. Application of equation 2 gave a 2 = 
0.252(C) 2'~ (r = 0.818). Therefore, weighting individual subject sets of C,t 
data according to 1/C~ is statistically justified in this case. 
Table IV lists values of ~/kel, B/(A + B), and ~/kel(1 + k 1 2 / k 2 1  ) calcu- 
lated for each subject using wi = 1/C 2. Since the ratio B/(A + B) is generally 
much less than unity, acetaminophen is definitely "two compartment" and 
poorly approximated by the one-compartment open model. Moreover, 
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Table  IV, Pharmacokinetic Parameters Calculated from Disposition Rate Constants Weighting 
According to 1/C~ 
Subject fl/ka fl/k~l(1 + klz/k2a ) B/(A + B)" 
1 0.746 0.923 0.667 
2 0.522 0.861 0.435 
3 0.0875 0.356 0.0272 
4 0,993 0.998 0.989 
5 0.155 0.365 0.0439 
6 0.162 0.478 0.0680 
7 0.238 0,250 0.0051 
8 0.666 0,907 0.590 
9 0.768 0,875 0.604 
10 0.204 0,451 0.160 
Average b 0.478 0.690 0.398 
C.V. (~)  69.8 39.0 85.6 
From average plasma level curve 
(1/CI) 2 0.532 0.685 0.274 
1/a~ 0.466 0.764 0.328 
aB/(A + B) = (k2x - f l ) / ( c t  - fl). 
bExcludes subject 7. 
since fl is not clearly small enough compared t o  k 21 (see Table II), B/(A + B) 
underestimates fl/ke~. Table IV also shows that the values of CCCF for sub- 
jects 3, 5, 6, 7, and 10 as well as for subject averages are much less than unity. 
Hence .4~ of acetaminophen cannot be accurately predicted by the one- 
compartment open model. A large error would also occur in the estimated 
loading dose if the one-compartment approximation were applied to acet- 
aminophen, because R A for the one-compartment model would be greater 
than that for the two-compartment case. For subjects 1, 2, 4, 8, and 9, on 
the other hand, A~ can be approximated well by the one-compartment 
model despite the fact that the data really obey the two-compartment model. 
Hence the one-compartment approximation would predict, by equation 7, 
that when z = tl/2 the loading dose would be 1.44 times the maintenance 
dose, where tl/2 -= 0.693//3. 
DISCUSSION 
The simultaneous fitting of plasma concentration-time data for each 
subject to Model I and equations A1 and A2 of the Appendix revealed that 
in general k~ > kA. Absorption-time plots based on the Loo-Riegelman 
method (4) gave results consistent with firs-t-order input kinetics. This sup- 
ports and quantifies previous observations by Albert et al. (2), who reported 
that when acetaminophen was administered in the form of a commercial 
tablet it was more rapidly absorbed than when it was administered as a soft 
gelatin capsule. Evaluation of the data in Table II also showed that the 
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apparent plasma clearance area remained constant intrasubject. Evidence for 
this is provided by a paired t-test in which a comparison of the means of the 
dose/area ratios following treatments A and B gave differences that tested 
not significant (t = 1.82, df = 8). This suggests that efficiencies of absorption 
of acetaminophen can be estimated by a direct comparison of areas under 
the C, t curves rather than by invoking the corrected area procedure described 
by Wagner (5). 
Simultaneous fitting of two or more sets of plasma data to a model is 
generally preferred to individual fitting since there is an appreciable increase 
in the degrees of freedom. The standard deviations of the estimated param- 
eters are consequently reduced (6). Nine parameters were estimated by 
simultaneous fitting of between 15 and 20 data points (depending on the 
magnitude oft0) rather than by use of six to ten data points for six parameters, 
as would be the case in individual fitting of these data. The parameters k 1 z, 
kzl, and kel were assumed constant intrasubject from treatment to treatment. 
Therefore, only one value of each was estimated. Initial estimates of these 
disposition rate constants obtained by use of an electronic calculator indicated 
that, indeed, this constancy assumption was justified with acetaminophen. 
Model I shows loss of drug from the inner compartment only. The 
data could have been fitted equally well to Model II with loss from the outer 
compartment or to Model III with loss from both compartments: 
ke~ 
FD at t = t o kok~k--~ 1/~ 
Model II 
(kJ2 > 
FD at t = t o ~ l/: 
Model III 
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Since these models are pharmacokinet ical ly  indistinguishable when only 
the central compar tment  is available for sampling, only three rate parameters  
can be determined in the disposition por t ion of  the model  (7) even though  
four microscopic rate constants  are pictorially depicted in Model  III .  I f  one 
wishes to calculate the values of  k12, k2t,  and kel for Model  II  or  k12, 
E 2 = k2x + (kel)2, and (ket)l for Model  I I I  f rom the parameters  estimated 
for Model  I, the convers ion equat ions are readily obtained. 
APPENDIX 
Equations Employed in Simultaneous Fitting 
For  t reatment  A : 
kACoF(k21 - a )e -~ ,~  (k21 - fl)e-a,'~ (k21 - ka) e-k~t'~] 
CA(t) L(-~A - ~ / ~ - ~  + (kA - fl)(~ - fl) + ~ - -  k - ~  -~k~A)J (A1) 
where (4 = t - t0A, c~ > fl, and C ~ = absorbed dose/V 1 following treat- 
ment  A. 
For  t reatment  B : 
CB(t) = kBC~ (k21 -- ~)-e-"~ + (k21 - fl)e -a~ + (kz~ - kB)e -k"'~]: (A2) 
L(kB - ~)(fl - o0 (kB - fl)(~ - fl) ~ -  k.~ ~ J  
where G = t - toB , a > fl, and C ~ = absorbed dose/V 1 following treat- 
ment  B. 
In  equat ions A1 and A2, 
0r = 1{(kl 2 + k21 + kel) + E(k~ 2 + k21 + kel)2 _ q.lg21~elJ--- I. 71/2~ (A3) 
Equations Employed in One-Compartment Approximations 
When  elimination occurs only from the central compar tment ,  
D 
Cl( t  ) - 1,11(o ~ _ fl)[(k21 - fi)e -~* - (k2~ - a )e  - ' t ]  (A4) 
Equat ion  A4 can be written as equat ion A5 : 
Cl( t  ) = A e - ' t  + B e - ~  (A5) 
Since 
it follows that  
D / V  1-= A + B =  C O (A6) 
C1/C ~ = [A/(A + B)] e -'~ + [B/(A + B)] e -pt (A7) 
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Therefore ,  
B / ( A  + B) = (k21 - fl)/(a - fl) 
Perr ie r  a n d  G i b a l d i  (8) showed  tha t  
x400 = ~--~O(3" Vdss = Vdss/Vd . . . .  9 FD/flz" 
Also, 
Hence ,  
(AS) 
(A9) 
Vas" = (1 + k~2/k21)V ~ (A10) 
Vd . . . .  ~-. V ~ ( k e , / f l )  (A11) 
Vdss/Vd . . . .  = (fl/kel)(1 + k lz /k21)  (A12) 
S u b s t i t u t i n g  e q u a t i o n  A12 in to  e q u a t i o n  A9 gives e q u a t i o n  A13:  
-4o~ = [(1 + k12/k20FD]/kelZ  (A13) 
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